Author

Pooja Saxena

Institutions: Medicago (Canada), McGill University

Observed institutions: Universidade de São Paulo, Medicago (Canada), University of Southampton, McGill University, Universidade Federal de São Paulo

ORCID: 0000-0002-3100-9740

Observed ORCID: 0000-0002-3100-9740

OpenAlex ID: A5064312334

Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine

2022 · Karen J. Hager, Gonzalo Pérez Marc, et al. · New England Journal of Medicine · 253

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities

2022 · Nathalie Charland, Philipe Gobeil, et al. · npj Vaccines · 73

Plant molecular farming in the wake of the closure of Medicago Inc

2023 · Eugenio Benvenuto, Inge Broer, et al. · Nature Biotechnology · 38

A genome‐edited N. benthamiana line for industrial‐scale production of recombinant glycoproteins with targeted N‐glycosylation

2023 · Benjamin Kogelmann, Stanislav Melnik, et al. · Biotechnology Journal · 21

Elimination of receptor binding by influenza hemagglutinin improves vaccine-induced immunity

2022 · Hilary E. Hendin, Pierre-Olivier Lavoie, et al. · npj Vaccines · 19

An oligosaccharyltransferase from Leishmania donovani increases the N-glycan occupancy on plant-produced IgG1

2023 · Gernot Beihammer, Julia König-Beihammer, et al. · Frontiers in Plant Science · 9

In planta expression of active bacterial GDP‐6‐deoxy‐ d ‐lyxo‐4‐hexulose reductase for glycan modulation

2023 · Benjamin Kogelmann, Roman Palt, et al. · Plant Biotechnology Journal · 6

Marked Reduction in Viral Load and Symptoms in Breakthrough COVID-19 Cases Following AS03-Adjuvanted Plant-Made VLP Vaccination

2023 · Hilary E. Hendin, Alexander Makarkov, et al. · SSRN Electronic Journal

Works count: 8

Citation count: 419

H-index: 6

I10-index: 5